Insights into the Mechanisms of the Acute Kidney Injury-to-Chronic Kidney Disease Continuum

Koji Takaori  Motoko Yanagita

Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Introduction

Acute kidney injury (AKI) is a very common disease associated with multiple organ failure, poor outcome, longer hospital stay, and higher medical cost. Accordingly, it has received a great deal of attention in recent years. In the United States, about 300,000 people die from AKI each year, and the presence of AKI increases the length of a patient’s hospital stay by 3.5 days [1]. Furthermore, it is recognized that AKI sometimes progresses to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Patients with AKI have a higher risk of developing CKD and ESRD, as a systematic review and meta-analysis by Coca et al. [2] has shown. Recent clinical trials have also
demonstrated that the severity and frequency of AKI are related to progression to CKD [3, 4]. While clinical epidemiology strongly supports the hypothesis that AKI contributes to progression to CKD or ESRD, the molecular mechanisms involved in the AKI-to-CKD continuum remain unclear. Proximal tubules are mainly damaged in AKI and repaired by their proliferation [5, 6]. Inadequate repair of proximal tubules might be involved in the progression to CKD. Here, we review the current knowledge of the mechanisms of the AKI-to-CKD continuum, especially the mechanism how injured proximal tubules trigger the progression of AKI-to-CKD.

### Mechanisms of the AKI-to-CKD Continuum

#### Fibrosis, Inflammation and Hypoxia: Possible Mechanisms of the AKI-to-CKD Continuum

One of the major hallmarks of CKD is interstitial fibrosis, characterized by scar-forming myofibroblasts whose origins remain a matter of controversy. We and other groups have shown that resident fibroblasts and pericytes, including erythropoietin (Epo)-producing cells, transdifferentiate into myofibroblasts and are the main contributors to fibrosis [7–9]. Recently, Kramann et al. [10] demonstrated that hedgehog (Hh)-responding perivascular Gli1+ cells, which constitute a small portion of platelet-derived growth factor-β+ fibroblasts, proliferate after AKI and have the features of progenitors of myofibroblasts.

Infiltration of inflammatory cells is another common feature of CKD. After AKI, various types of inflammatory cells invade the kidney, including neutrophils, monocytes/macrophages, dendritic cells and lymphocytes; these inflammatory cells are also involved in the repair process after AKI [11, 12]. Macrophages play central roles in kidney injury and repair, and animal models have demonstrated the presence of 2 types of macrophages after AKI. While M1 macrophages migrate to the kidney immediately after the injury and produce proinflammatory molecules, M2 macrophages emerge in the recovery phase of AKI and secrete profibrotic cytokines. M2 macrophages may help tubular cell proliferation and repair in the resolution of the acute phase of the injury [13], but the sustained infiltration of M2 macrophages leads to fibrosis and contributes to the progression to CKD. Indeed, it is reported that the number of the infiltrated M2 macrophages correlates with the degree of interstitial fibrosis in renal biopsy sample of IgA nephropathy [14].

Loss of peritubular capillaries is another common finding after AKI. Quantitative assessment by fluorescence microangiography revealed that capillary numbers and areas were decreased after AKI in proportion to the degree of the injury [15]. Loss of peritubular capillaries in AKI causes hypoxia, leading to the progression to CKD. Hypoxia damages tubular epithelial cells, activates inflammatory cells and fibroblasts, and finally leads progresses to CKD [16].

#### Selective Proximal Tubule Injury Leads to CKD

**Animal Models Showing That Proximal Tubule Injury Is Sufficient to Cause CKD**

The proximal tubule is the main site of injury during AKI, and several groups have hypothesized that injured proximal tubules play important roles in the progression of CKD [17, 18]. Pathological findings indicate that interstitial fibrosis emerges around injured proximal tubules, lending further support to this hypothesis. For the purpose of testing this hypothesis, however, traditional AKI models caused by ischemic reperfusion injury, toxins and sepsis are not ideal because these injuries affect various types of cells at the same time, so that the models cannot identify the specific cell type that is important in the progression to CKD. To restrict the primary injury to one specific cell population at a time, Cre-LoxP technology in combination with the toxin receptor-mediated cell knockout (TRECK) method has been utilized. Gracic et al. [17] utilized a mouse model in which the simian diphtheria toxin (DT) receptor is expressed on nephron epithelial cells; by adjusting the dose and timing of DT administration, they induced preferential proximal tubule-specific injury, and demonstrated that recurrent proximal tubular injuries drive interstitial fibrosis and glomerulosclerosis. Our groups utilized the TRECK method together with proximal tubule-specific CreERT2 mice [5], in which the administration of tamoxifen activates the inducible form of Cre, and successfully induced selective proximal tubule injuries [18]. By adjusting the doses of tamoxifen and DT, we could induce various types of proximal tubule injuries in this mouse strain. We showed that selective proximal tubule injury causes the transition of fibroblasts to myofibroblasts around the injured proximal tubules, leading to fibrosis and reduced Epo production (fig. 1). We also found that fibrosis was reversible when proximal tubule injury was mild, while recurrent mild proximal tubule injuries caused sustained interstitial fibrosis together with inflammation. We further demonstrated the existence of a threshold level of proximal tubule injury sufficient to induce interstitial fibrosis as...
well as distal tubule injury. We also focused on the changes in glomeruli after selective proximal tubule injury, and found that glomeruli remained structurally normal after a single severe proximal tubule injury, but progressed to sclerosis and atubular glomeruli after repeated mild proximal tubule injuries [18]. Taken together, our evidence demonstrates that selective proximal tubule injuries cause several features of CKD, and that the severity and frequency of proximal tubule injuries determine progression to CKD. When proximal tubule injury is severe, the proximal tubules can become shorter after repair. Protecting the proximal tubules is essential for halting the progression from AKI to CKD.

How Does Proximal Tubule Injury Affect Fibroblast Activation and Inflammatory Changes?

Kidney injury molecule 1 (KIM-1) expression in the proximal tubules is involved in the progression to CKD. After injury, KIM-1 is upregulated in the proximal tubules, where it acts as a receptor for phosphatidylserine-mediated phagocytosis. While acute expression of KIM-1 blocks proinflammatory signaling and ameliorates tubule injury [19], prolonged expression of KIM-1 induces sustained inflammation with fibrosis [20]. Furthermore, other signaling pathways in the proximal tubules, such as Hh-Gli, Wnt, Notch and transforming growth factor β (TGF-β), have been reported to induce the transdifferentiation of fibroblasts to myofibroblasts [21]. Bechtel et al. [22] demonstrated that TGF-β causes epigenetic modification of fibroblasts and sustained fibrosis. Maarouf et al. [23] recently demonstrated that the activation of Wnt signaling in the proximal tubules directly induces fibrosis without inflammation.

Maladaptive Repair of Proximal Tubules

Previously, we performed a lineage tracing analysis of proximal tubules and demonstrated that injured proximal tubules repair themselves through their own proliferation [5]. We have also examined the limits of the proximal tubules’ capacity for self-repair after severe injury by demonstrating that the proximal tubules are shortened after such repairs (fig. 1). Together with the results of our TRECK analysis, these previous results indicate that severe and frequent proximal tubule injury and inadequate repair are the key determinants of the AKI-to-CKD continuum (fig. 1).

As one of the key cellular mechanisms in the AKI-to-CKD progression, maladaptive repair after AKI is worth examining. Some researchers have focused on cell cycle arrest in tubular cells after AKI. Yang et al. [24] utilized various AKI models to demonstrate that proximal tubule cells whose cell cycles are arrested at the G2/M checkpoint activate c-jun NH2-terminal kinase signaling and upregulate the production of profibrotic cytokines, such as TGFβ1 and connective tissue growth factor, while pharmacological inhibition of G2/M-arrested cells attenuates fibrosis. Recently, cell-cycle-arrest biomarkers such as urine insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 have been proven useful for detecting AKI in humans [25].
Conclusion

In summary, several cell populations, factors and molecules are involved in the AKI-to-CKD continuum, a clinically important process. The proximal tubule is the main site of injury in AKI, and injured proximal tubules play important roles in the progression of CKD. Fibrosis after AKI is, at least in part, a consequence of proximal tubule injury, and therapeutic strategies targeting fibrosis might not be sufficient to halt AKI-to-CKD progression. Inadequate repair of the proximal tubules is considered to be the key cellular mechanism in the AKI-to-CKD continuum, and therapeutic strategies to protect the proximal tubules and promote their repair capacity are essential. Modulating molecules in injured proximal tubules will be helpful for halting the progression to CKD. For example, intervention aimed at G2/M arrested cells in proximal tubules might be considered the novel therapeutic strategies. Indeed, histone deacetylase inhibitors or p53 inhibitors have been shown to ameliorate fibrosis by decreasing G2/M arrested cells in animal models [24, 26]. Translation of these strategies to humans will help the prevention of AKI-to-CKD continuum.

Acknowledgement

Present address of K.T.: Department of Nephrology, Otsu Red-Cross Hospital, Shiga, Japan.

Disclosure Statement

K.T. has no conflicts of interest to declare. M.Y. is on the advisory board of Astellas and receives research grants from Astellas, Chugai, Daiichi Sankyo, Fujifyakuhin, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Nippon Boehringer Ingelheim, and Torii.

References


